Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
Thomas Nyström; Johan Bodegard; David Nathanson; Marcus Thuresson; Anna Norhammar; Jan W. Eriksson
Author Information: Unit for Diabetes Research, Division of Internal Medicine, Department of Clinical Science and Education, Karolinska Institute
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.